Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call
June 14, 2022 16:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022...
Treosulfan Pivotal Study Results Published
June 06, 2022 08:30 ET
|
Medexus Pharmaceuticals Inc
Study’s primary endpoint and key secondary endpoints were metStudy found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality...
Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA
May 24, 2022 17:05 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, May 24, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received...
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA
April 22, 2022 08:30 ET
|
Medexus Pharmaceuticals Inc
Additional data collection and analysis reconfirms confidence in New Drug Application for TreosulfanNDA resubmission date consistent with previously announced timelineFDA decision still expected...
Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 19, 2022 16:20 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, April 19, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) will be presenting at the Bloom Burton & Co. Healthcare Investor Conference...
Medexus to Participate in the 34th Annual Roth Conference
March 09, 2022 08:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, March 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be participating in...
Medexus Pharmaceuticals Announces Deal for Gleolan in the United States
March 01, 2022 07:15 ET
|
Medexus Pharmaceuticals Inc
Medexus has acquired exclusive rights to commercialize Gleolan in the United States,complementing Medexus’s existing rights to Gleolan in Canada Gleolan is an optical imaging agent currently...
Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
February 14, 2022 08:00 ET
|
Medexus Pharmaceuticals Inc
Medexus will implement a NCIB in respect of its6% unsecured convertible debentures due 2023 NCIB will commence on February 16, 2022 and is expected to continue for up to 12 months NCIB purchases...
Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021
February 09, 2022 18:30 ET
|
Medexus Pharmaceuticals Inc
Achieved $21.3 million revenue driven by a recovery in IXINITY sales Treosulfan NDA resubmission expected in second calendar quarter 2022 with final FDA decision anticipated 2-6 months after...
Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference
February 01, 2022 16:15 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be presenting at The...